Efficient Synthesis of Boron-containing α-acyloxyamide Analogs Via Microwave Irradiation

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2013 Aug 23

PMID 23966074

Citations 2

Authors

Chih-Cheng Chai

Pin-Yi Liu

Chia-Hung Lin

Hsien-Chi Chen

Yang-Chang Wu

Fang-Rong Chang

Po-Shen Pan

Affiliations

Soon will be listed here.

Abstract

In this report, a Passerini three-component reaction utilizing boron-containing carboxylic acids or aldehydes is discussed. The reaction was carried out in water and facilitated by the use of microwave irradiation. This methodology allowed for the efficient formation of a broad range of boron-containing α-acyloxyamides under mild conditions within a short time. Two series of boron-containing α-acyloxyamides were synthesized and subsequently screened for cytotoxicity using the MTT cell viability assay. Two potential lead compounds were found to have potent activity against the HepG2 cancer cell line, demonstrating the potential of this methodology for use in the development of novel pharmaceuticals.

Citing Articles

Protection-Free Strategy for the Synthesis of Boro-Depsipeptides in Aqueous Media under Microwave-Assisted Conditions.

Qiu S, Liu P, Wang B, Chen P, Xiao J, Hsu T Molecules. 2022; 27(7).

PMID: 35408725 PMC: 9000886. DOI: 10.3390/molecules27072325.

Isocyanide-Based Multicomponent Reactions of Free Phenylboronic Acids.

Neochoritis C, Zarganes-Tzitzikas T, Novotna M, Mitrikova T, Wang Z, Kurpiewska K Eur J Chem. 2021; 2019(35):6132-6137.

PMID: 33981465 PMC: 8112803. DOI: 10.1002/ejoc.201901187.

References

Stoukides C, McVoy H, Kaul A . Candesartan cilexetil: an angiotensin II receptor blocker. Ann Pharmacother. 2000; 33(12):1287-98. DOI: 10.1345/aph.19005. View

Groll M, Berkers C, Ploegh H, Ovaa H . Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 2006; 14(3):451-6. DOI: 10.1016/j.str.2005.11.019. View

Baker S, Akama T, Zhang Y, Sauro V, Pandit C, Singh R . Identification of a novel boron-containing antibacterial agent (AN0128) with anti-inflammatory activity, for the potential treatment of cutaneous diseases. Bioorg Med Chem Lett. 2006; 16(23):5963-7. DOI: 10.1016/j.bmcl.2006.08.130. View

Domling , Ugi I . Multicomponent Reactions with Isocyanides. Angew Chem Int Ed Engl. 2000; 39(18):3168-3210. DOI: 10.1002/1521-3773(20000915)39:18<3168::aid-anie3168>3.0.co;2-u. View

Hideshima T, Richardson P, Chauhan D, Palombella V, Elliott P, Adams J . The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001; 61(7):3071-6. View

Garcia-Soria G, Gonzalez-Galvez G, Argoud G, Gerstman M, Littlejohn 3rd T, Schwartz S . The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2008; 10(4):293-300. DOI: 10.1111/j.1463-1326.2008.00868.x. View

OFarrell A, van Vliet A, Farha K, Cherrington J, Campbell D, Li X . Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects. Clin Ther. 2007; 29(8):1692-705. DOI: 10.1016/j.clinthera.2007.08.005. View

Sung B, Hwang K, Jeon Y, Lee J, Heo Y, Kim J . Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature. 2003; 425(6953):98-102. DOI: 10.1038/nature01914. View

Kusebauch U, Beck B, Messer K, Herdtweck E, Domling A . Massive parallel catalyst screening: toward asymmetric MCRs. Org Lett. 2003; 5(22):4021-4. DOI: 10.1021/ol035010u. View

10.

Tran T, Quan C, Edosada C, Mayeda M, Wiesmann C, Sutherlin D . Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP. Bioorg Med Chem Lett. 2006; 17(5):1438-42. DOI: 10.1016/j.bmcl.2006.11.072. View

11.

Yang W, Gao X, Wang B . Boronic acid compounds as potential pharmaceutical agents. Med Res Rev. 2003; 23(3):346-68. DOI: 10.1002/med.10043. View

12.

Gupta R, Walunj S, Tokala R, Parsa K, Singh S, Pal M . Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009; 10(1):71-87. DOI: 10.2174/138945009787122860. View

13.

Adams J . The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003; 29 Suppl 1:3-9. DOI: 10.1016/s0305-7372(03)00081-1. View

14.

Kumar J, Jonnalagadda S, Mereddy V . An Efficient Boric Acid Mediated Preparation of α-Hydroxyamides. Tetrahedron Lett. 2010; 51(5):779-782. PMC: 2808032. DOI: 10.1016/j.tetlet.2009.12.008. View

15.

Domling A . Recent developments in isocyanide based multicomponent reactions in applied chemistry. Chem Rev. 2006; 106(1):17-89. DOI: 10.1021/cr0505728. View

16.

Amin S, Kupper F, Green D, Harris W, Carrano C . Boron binding by a siderophore isolated from marine bacteria associated with the toxic dinoflagellate Gymnodinium catenatum. J Am Chem Soc. 2007; 129(3):478-9. DOI: 10.1021/ja067369u. View

17.

Winder T, Lenz H . Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev. 2010; 36(7):550-6. DOI: 10.1016/j.ctrv.2010.03.005. View

18.

Andreana P, Liu C, Schreiber S . Stereochemical control of the Passerini reaction. Org Lett. 2004; 6(23):4231-3. PMC: 4134661. DOI: 10.1021/ol0482893. View

19.

Adams J . The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004; 4(5):349-60. DOI: 10.1038/nrc1361. View

20.

Baker S, Zhang Y, Akama T, Lau A, Zhou H, Hernandez V . Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem. 2006; 49(15):4447-50. DOI: 10.1021/jm0603724. View